Conclusions and Final Recommendations
In intracavitary therapy, due to the high dose-rate gradient, the specification of the target absorbed dose as that dose observed at one (or several) reference point(s) within the target volume or close to the sources, does not appear to be meaningful. Under these conditions, the same approach to reporting as in external beam therapy cannot be recommended.
The following are proposed in this Report (see Table  0 .1).
First, as already pointed out in ICRU Report 29 (ICRU, 1978) , any method of specification will be meaningful only to the extent that the treatment technique has been completely described.
Second, the total reference air kerma should be stated. For a given method of application (source geometry and relative loads), the doses delivered at the different tissues or organs are directly proportional to the total reference air kerma.
Third, it is recommended that the reference volume be described in terms of the height, width and thickness of the volume enclosed in the 60 Gy isodose surface for cervix-carcinoma treatment by low dose rates. For higher dose rates a dose level lower than 60 Gy has to be selected.
Fourth, the absorbed dose at reference points in organs at risk (rectum, bladder) should be determined (computed or measured) and expressed in well-codified ways to provide additional safety limits.
In addition, the absorbed dose(s) at reference point(s) related to bony structures (lymphatic trapezoid and pelvic-wall reference points) should also be reported.
Finally, the time-dose pattern should be completely specified. 
